Posts tonen met het label innovation. Alle posts tonen
Posts tonen met het label innovation. Alle posts tonen

27 augustus 2019

Public Equity Impact Investing THEORIES of CHANGE (Part I)

The limited offer of (inclusive) impact investment products steers investors towards different(iated) impact levels, preferred investment products & impact assets allocation.

E.g. in fixed income green or muni bonds, health (property), farmland REITs, sustainable real estate or SDG investment funds
Of course all investments have impact, but impact investing aims at doing well & doing good, which in today's investment market varies from doing less harm (the largest offer in investment products) to having positive: broad and/or deep impactIt is a developing universe with growing impact transparency & increasing product innovation.

Overwhelmed by the choices, discourse & reasoning in the impact investment universe? 

Just as their financial strategy or mandate defines the risk appropriate return goals, defining a Theory of Change is a strategy for impact investors to define how to achieve impact: societal & environmental goals

I will sketch impact investment choices based on  i.e. actual market offerings & trends such as Exclusion, Engagement, ESG Integration and more impact ambitious goals such as SDG contribution as Theories of Change. Ethical, ideological or sustainability motivations will improve investors understanding of impact dilemma's & choices.

THEORIES OF CHANGE are like INVESTMENT MANDATES: guiding principles to achieve the impact goals.'Balancing impact & return' mandates -the preferred strategy for large impact investors (theGIIN Global Annual Surveys) can be exclusion guidelines and/or allocation to low(er) ESG (Environment, Social & Governance) Risk Exposure and / or Selection of ESG Opportunities, Best-in-Class investments and SDG & (Deep) Impact Investments.

Overlapping of ESG & IRD = WIN WIN
ESG Environment, Social & Governance activities 
&
IRD: Innovation, Research & Development investments.

Using less natural resources such as commodities/extractives, energy, (sweet) water requires Innovations ie Research & Development in production processes lower production & societal costs. E.g. discovering or developing alternative resources, more efficient production and re/upcycling & waste management. 

Tech Optimist or Tech Dystopian? 
Human Resources i.e. PEOPLE, Labor are indispensable to develop & steer (Tech4Good) Automation & Robotisation to ease hard labor and assure global access to Basic Needs.

In Human Resources & Marketing ageing in developing markets, population growth &  the call for inclusive economies offering Income, Employment & (Global) Access to Basic Needs such as Security & Shelter, Food & Clean Water, Healthcare, Education, Opportunities (Hope) & a Livable Planet demand corporations reinventing themselves.

Corporations i.e. Capitalism choosing Impact Growth Strategies: focus IRD investments towards impact services & products are attractive investments. 

Their MOAT (long term economic perspective) is WIDE as successful companies will be the multinationals of the future providing economic growth/innovation, employment & socialtal solutions: impact services & products.

#TheTimestheyareChanging: ''Even America’s famously ruthless bosses agree. This week more than 180 of them, including the chiefs of Walmart and JPMorgan Chase, overturned three decades of orthodoxy to pledge that their firms’ purpose was no longer to serve their owners alone, but customers, staff, suppliers and communities, too.'' @TheEconomist 22aug1029

Part 1: EXCLUSION strategies as Impact Investment Theory of Change.

































































































































































Want to read ahead? 
Go to https://www.slideshare.net/alcanne/impact-investing-theories-of-change-145289451 page 9


2 februari 2018

Impact Investment Rating van een Impact Tech Medidata Solutions

Medidata Solutions krijgt Impact Investment Rating©: BUY.

Waarom? de kernactiviteiten & ambitie(s), het fonds is beschikbaar, betaalbaar & aantrekkelijk als Growth Stock, want het krijgt positieve analisten adviezen en heeft institutionele investeerders.

Impact Investment Rating©
Is gebaseerd op de kenmerken van inclusive impact investing:

IMPACT NIVEAU's:
3ESG kansen,
4: Wereldwijde Gezondheidsbedreigingen
als essentiele partner voor snelle betere klinische tests van medicijnen en therapieën; en
5Toegang tot Basisbehoefte Gezondheidszorg 

Medidata Solutions is actief in #SDG3: Health & Wellbeing & #SDG9: Innovation  & #SDG12: Sustainable Consumption & Production (efficiency).


PRODUCT KENMERKEN:
Medidata Solutions aandelen zijn beschikbaar & betaalbaar. Verkrijgbaar bij DeGIRO & ABNAMRO en het wordt verhandeld op NASDAQ als MDSO voor circa 70US$, op de Borse Frankfurt voor 56e & de Zwitserse beurs.
ISIN: US58471A1051

Medidata Solutions aandelen zijn in 2013 gesplitst om inclusive te blijven. Altijd een positive move :), in de VS zijn instapkosten en drempels hoger dan hier. Andere voordelen volgens Investopedia: liquiditeit & aandacht van investeerders.

Medidata Solutions betaalt geen dividend en heeft geen Dividend re-Investment Plan (DRIP). 

Het  is wel aantrekkelijk als Growth Stock. Het krijgt positieve analisten adviezen: 9 buy adviezen (2 hold) van 11 analisten volgens CNNMoney en Yahoo Finance: 2 strong buy, 6 buy 2 hold.
Prijsdoel is 69US$ en de koers is 70US$. Groei schattingen: 15-20%.
1 Volatility alert (Cmlviz, nov 2017).
Medidata Solutions vermeldt 11 Analisten op haar Investor Relations pagina.

Medidata Solutions heeft grote institutionele investeeders, asset managers aandeelhouders: Blackrock: 11,3%  Fidelity 6,8% (↓ 13%), Vanguard 6,6%, Sands Cap. 6%...

MDSO is opgenomen in 82 ETFs (etfdbase). Top holding, 2%, in Ark IM ETF Innovation (563million US$ AuM) & 3% Genomics Revolution (90million US$ AuM). Ark IM is a specialist in 'disruptive innovators'. Ook > 2% in Guggenheim S&P 400 MidCap Pure Growth ETF (626million US$ AuM).

IMPACT
JV 2017: We offer: • faster trial results; • scalability; • improved data quality and minimization of risk; • enhanced investigator experience; • interoperability to support ecosystem; and • global connectivity across sponsor & investigator sites.

MissieMake clinical trials run better.
Visie: Using the latest technology to help our life science clients bring their life-saving new treatments to the public.
Impact: Improving Clinical Research design, conduct & analysis.
Principes: Integrity, Partnership, Inventiveness, Humility, Nimbleness, Tenacity, Inclusiveness, and Caring. (in vacancy global account manager)


IMPACT METRICS
Output: ''We have conducted +12000 clinical trials for 3,4 million patients, in over 130 countries''.

Company CSR page: Medidata Foundation, donations in kind, volunteerism, Environment Goal 2017: 90% offices Leed certificied.
Investor Relations pagina: Code of Business Conduct & Code of Ethics.

CSR Hub (117,734+ companies) score is onder IT sector gemiddelde.
Total 45: Employee 52, Community 45, Environment 43, Governance 42.

Sector ESG kansenClinical trials SaaS: Artificial Intelligence (AI), m(obile)Health, Internet of (Medical) Things (IoMT), Big Data, social media. Technology changes clinical trials.

Sector ESG Risico's & Issues, patiënten selectie & privacy, gesponsord onderzoek & transparantie.

Medidata Solutions lawsuits over patenten en werknemersrechten (met concurrenten), het is opgelicht (408miljoen US$, computer fraude) maar won de rechtszaak.

Impact opschaling
Cliënten: +400 (850) cliënten. We serve 18 of the world's top 25 global pharmaceutical companies & product developers...

Innovatie Awards: ''Scrip Award for Best Tech. Dev. for Medidata SCA (2017) “Best Tech. Dev. for Medidata Payment (2017) see Q reports.
Medidata Solutions geeft zelf innovatie awards 2017 aan klanten en toeleveranciers als ''Architects of Hope''. Nogal briljante marketing + impact incentive.
De samenwerking met klant TESARO, Inc. won “Clinical Partnership of the Year” op de 2nd Clinical and Research Excellence (CARE) Awards 2017. (SupplyChain)

Clinical trial SaaS aquisities: 5 & VC investeringen: 4 in (Bron: Crunchbase)

IMPACT ASSET CLASSES
Mediata Solutions biedt Impact Tech, een efficiency katalysator voor Basisbehoefte Gezondheidszorg: farma, productontwikkeling, wetenschappelijk onderzoek aan zieken, oudere mensen en kinderen in ontwikkelde & opkomende landen en ontwikkelingslanden omdat het in 130 landen wordt gebruikt.

IMPACT INVESTMENT TYPE: DIRECT
Medidata Solutions Software as a Service voor klinische tests is een essentieel product in de ontwikkeling van medicijnen (supply chain).
Basisbehoefte: gezondheidzorg medicijnen

SAMENVATTING
Medidata Solutions biedt Software as a Service (SaaS) voor klinische tests voor snellere, betere medicijn- en therapieontwikkeling.
Opschaling: Het heeft +400 (850) klanten waaronder opkomende biotechnologie ondernemingen, de grote farmaceuten, ''cutting-edge device & diagnostic'' ondernemingen, innovatieve wetenschappelijk onderzoek sites, grote overheidsinstellingen & anderen... Honderden life science organisaties hebben het platform gebruikt, in meer dan 12000 tests voor 3,4 miljoen patiënten in ruim 130 landen. (incl. ontwikkelingslanden)
Groeiprognose (fin): 15 a 20% per jaar (Yahoo Finance). 

Geen dividend: Growth Stock, ruime koop consensus en institutionele investeerders. 70US$, verkrijgbaar op Nasdaq, Borse Frankfurt & Swiss SE.

AANBEVELINGEN
(Geïntegreerde) Rapportage van CSR, ESG, Impact Key Performance Indicatoren. Ontwikkeling van sector specifieke impact standaarden & een monitoring systeem (klinische tests productontwikkelingsketen) en het verbinden van ''output'' aan ''outcome'' en impact van versnelde ontwikkeling van medicijnen voor patiëntenpopulaties.

Blogger = micro investor

Inclusive Impact Investment
made easy with
Impact Investment Rating©

Columns & Rating verzoekenhttps://nl.linkedin.com/in/alcannehoutzaager
Twitter @alcanne

(site wordt binnenkort gerelaunched)